ATVB In Focus Lipoproteins, Inflammation, and Atherosclerosis

Apolipoprotein A5 (APOA5) is a newly described member of the apolipoprotein gene family whose initial discovery arose from comparative sequence analysis of the mammalian APOA1/C3/A4 gene cluster. Functional studies in mice indicated that alteration in the level of APOA5 significantly affected plasma triglyceride concentrations. Mice that overexpressed human APOA5 displayed significantly reduced triglycerides, whereas mice that lacked apoa5 had a large increase in this lipid parameter. Studies in humans have also suggested an important role for APOA5 in determining plasma triglyceride concentrations. In these experiments, polymorphisms in the human gene were found to define several common haplotypes that were associated with significant changes in triglyceride concentrations in multiple populations. Several separate clinical studies have provided consistent and strong support for the effect with 24% of whites, 35% of blacks, and 53% of Hispanics who carry APOA5 haplotypes associated with increased plasma triglyceride levels. In summary, APOA5 represents a newly discovered gene involved in triglyceride metabolism in both humans and mice whose mechanism of action remains to be deciphered. (Arterioscler Thromb Vasc Biol. 2003;23:529534.)

[1]  J. Sasaki,et al.  An apolipoprotein CIII marker associated with hypertriglyceridemia in Caucasians also confers increased risk in a west Japanese population , 1995, Human Genetics.

[2]  M. Olivier,et al.  Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides. , 2002, Human molecular genetics.

[3]  Jonathan C. Cohen,et al.  Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels. , 2002, Human molecular genetics.

[4]  S. Tomura,et al.  Association found between the promoter region polymorphism in the apolipoprotein A-V gene and the serum triglyceride level in Japanese schoolchildren , 2002, Human Genetics.

[5]  J. Ribalta,et al.  Newly identified apolipoprotein AV gene predisposes to high plasma triglycerides in familial combined hyperlipidemia. , 2002, Clinical chemistry.

[6]  R. Chamuleau,et al.  Adenoviral overexpression of apolipoprotein A-V reduces serum levels of triglycerides and cholesterol in mice. , 2002, Biochemical and biophysical research communications.

[7]  P. Reitsma,et al.  Apolipoprotein A-V , 2001, The Journal of Biological Chemistry.

[8]  Jonathan C. Cohen,et al.  An Apolipoprotein Influencing Triglycerides in Humans and Mice Revealed by Comparative Sequencing , 2001, Science.

[9]  L. Pennacchio,et al.  Genomic strategies to identify mammalian regulatory sequences , 2001, Nature Reviews Genetics.

[10]  P. Talmud,et al.  Contribution of Apolipoprotein C-III Gene Variants to Determination of Triglyceride Levels and Interaction With Smoking in Middle-Aged Men , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[11]  Lior Pachter,et al.  VISTA : visualizing global DNA sequence alignments of arbitrary length , 2000, Bioinform..

[12]  C. Lawrence,et al.  Human-mouse genome comparisons to locate regulatory sites , 2000, Nature Genetics.

[13]  R. Hardison.  Conserved noncoding sequences are reliable guides to regulatory elements. , 2000, Trends in genetics : TIG.

[14]  P. Denéfle,et al.  Structure and interfacial properties of chicken apolipoprotein A-IV. , 2000, Journal of lipid research.

[15]  R. Cantor,et al.  Association of plasma lipids and apolipoproteins with the insulin response element in the apoC-III promoter region in familial combined hyperlipidemia. , 1999, Journal of lipid research.

[16]  S. Brunak,et al.  SHORT COMMUNICATION Identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites , 1997 .

[17]  J. Breslow,et al.  Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein Cl. , 1996, The Journal of clinical investigation.

[18]  Dan S. Prestridge,et al.  SIGNAL SCAN 4.0: additional databases and sequence formats , 1996, Comput. Appl. Biosci..

[19]  A. Lupas.  Prediction and analysis of coiled-coil structures. , 1996, Methods in enzymology.

[20]  J. Breslow,et al.  An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3' untranslated region polymorphisms. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[21]  C. Shoulders,et al.  Variation at the apo AI/CIII/AIV gene complex is associated with elevated plasma levels of apo CIII. , 1991, Atherosclerosis.

[22]  J. Breslow,et al.  Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. , 1990, Science.

[23]  M. Kozak.  An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs. , 1987, Nucleic acids research.

[24]  J. Scott.  The human apolipoprotein genes. , 1987, Oxford surveys on eukaryotic genes.

[25]  M. Boguski,et al.  Evolution of the apolipoproteins. Structure of the rat apo-A-IV gene and its relationship to the human genes for apo-A-I, C-III, and E. , 1986, The Journal of biological chemistry.

[26]  S. Karathanasis.  Apolipoprotein multigene family: tandem organization of human apolipoprotein AI, CIII, and AIV genes. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[27]  G. Bruns,et al.  Human Apolipoprotein A‐I‐C‐III Gene Complex is Located on Chromosome II , 1984, Arteriosclerosis.